ASTELLAS PHARMA

🇯🇵Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/
openpr.com
·

Global Prostate Cancer Treatment Market Size - By Product

Prostate Cancer Treatment Market growth driven by rising incidence, awareness, and advances in technologies like immunotherapy and targeted biologics. Market expected to grow at 5.00% CAGR from 2024 to 2031, supported by healthcare infrastructure investments and personalized medicine.

Researchers Aim to Confirm Benefits of Non-Hormonal Therapy for Certain Prostate Cancer Patients

A Phase II trial showed AstraZeneca's Lynparza (olaparib) effective in treating recurrent prostate cancer without hormone therapy, prompting larger follow-up studies in biomarker-selected subgroups. Lynparza, a PARP inhibitor, demonstrated efficacy in patients with homologous recombination repair gene mutations, particularly BRCA2, with higher response rates than seen with hormonal suppression. The study suggests that not all prostate cancer patients need hormone therapy and highlights the need for biomarker-selected trials to identify responders.
contemporaryobgyn.net
·

First patient dosed in trial evaluating fezolinetant for VMS in breast cancer patients

First patient dosed in phase 3 HIGHLIGHT 1 trial evaluating fezolinetant for moderate to severe vasomotor symptoms (VMS) in breast cancer patients on adjuvant endocrine therapy.
© Copyright 2024. All Rights Reserved by MedPath